Autor(en)

Graff-Radford, Neill R. (ed.):

Verlag / Jahr

Philadelphia : Saunders, 2007.

Format / Einband

Original hardcover. Originalbroschur. XI; 288 p.

Sprache

Englisch

Gewicht

ca. 540 g

ISBN

1416050922

EAN

9781416050926

Bestell-Nr

1188321

Bemerkungen

Small abrasions on the cover. Otherwise good and clean. - Einband leicht berieben. Sonst gut und sauber. - Contents: Preface -- Neill R. Graff-Radford -- Alzheimer's Disease and Mild Cognitive Impairment -- Brendan J. Kelley and Ronald C. Petersen -- As our society ages, age-related diseases assume increasing prominence as both personal and public health concerns. Disorders of cognition are particularly important in both regards, and Alzheimer's disease is by far the most common cause of dementia of aging. In 2000, the prevalence of Alzheimer's disease in the United States was estimated to be 4.5 million individuals, and this number has been projected to increase to 14 million by 2050. Although not an inevitable consequence of aging, these numbers speak to the dramatic scope of its impact. This article focuses on Alzheimer's disease and the milder degrees of cognitive impairment that may precede the clinical diagnosis of probable Alzheimer's disease, such as mild cognitive impairment. -- Genetics of Alzheimer's Disease: A Centennial Review Nilüfer Ertekin-Taner -- Alzheimer's disease (AD) genetics may be one of the most prolifi- cally published areas in medicine and biology. Three early-onset AD genes with causative mutations (APP, PSEN1, PSEN2) and one late-onset AD susceptibility gene, apolipoprotein E (APOE), exist with ample biologic, genetic, and epidemiologic data. Evidence suggests a significant genetic component underlying AD that is not explained by the known genetic risk factors. This article summarizes the evidence for the genetic component in AD and the identification of the early-onset familial AD genes and APOE, and examines the current state of knowledge about additional AD susceptibility loci and alleles. The future directions for genetic research in AD as a common and complex condition are also discussed. -- An Update on the Amyloid Hypothesis -- Christopher B. Eckman and Elizabeth A. Eckman -- Alzheimer's disease (AD) is a devastating neurodegenerative disease. To rationally develop novel therapeutic and/or preventative agents for AD, an understanding of the etiology and pathogenesis of this complex disease is necessary. This article examines the evidence for the amyloid hypothesis of AD pathogenesis and discusses how it relates to the neurological and neuropathological features of AD, the known genetic risk factors and causative mutations, and the heightened risk associated with advanced age. -- Frontotemporal Lobar Degeneration -- Keith A. Josephs -- Frontotemporal lobar degeneration (FTLD) is a syndromic diagnosis that encompasses at least three different variants. Imaging modalities are clinically useful in FTLD, although pathology remains the gold standard for definitive diagnosis. To date, four different genes have been identified that account for FTLD. -- The Genetics of Frontotemporal Dementia -- Kristoffer Haugarvoll, Zbigniew K. Wszolek, and Michael Hutton -- This article describes the remarkable progress that has been made over the past decade in identifying the genetic contribution to fron-totemporal dementia. The clinical and neuropathologic features of frontotemporal dementia with parkinsonism linked to chromo-some 17 and the nature of the mutations in the progranulin and microtubule-associated protein tau genes are emphasized. -- Subcortical Ischemic Vascular Dementia -- Helena C. Chui -- Subcortical ischemic vascular dementia (SIVD) has been proposed as a subtype of vascular cognitive impairment. MRI often discloses "silent" hyperintensities in 20% to 40% of community-dwelling elderly. Efforts to relate MRI-measured lacunes and white matter changes to cognitive impairment have not been straightforward. The possibility that Alzheimer's disease pathology contributes to cognitive impairment increases with age. A rare disorder known as cerebral autosomal dominant arteriopathy with subcortical infarctions and leukoencephalopathy (CADASIL) provides an opportunity to study SIVD in the absence of Alzheimer's disease. Lacunes and deep white matter changes are associated with dysex- ecutive syndrome. Hypertension, the leading risk factor for sporadic SIVD, is treatable. High priority must be given to reducing vascular risk profiles. -- Dementia with Lewy Bodies -- Tanis J. Ferman and Bradley F. Boeve -- The advent of new immunostains have improved the ability to detect limbic and cortical Lewy bodies, and it is evident that dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia, after Alzheimer's disease (AD). Distinguishing DLB from AD has important implications for treatment, in terms of substances that may worsen symptoms and those that may improve them. Neurocognitive patterns, psychiatric features, extrapyramidal signs, and sleep disturbance are helpful in differentiating DLB from AD early in the disease course. Differences in the severity of cholinergic depletion and type/distribution of neuropathology contribute to these clinical differences. -- Parkinson-Related Dementias -- Bradley F. Boeve -- Recent advances in neurogenetics, molecular biology, and immunocytochemical staining methods have expanded the spectrum of neurodegenerative disorders now known to cause dementia associated with parkinsonism. This review concentrates on those rare disorders in which cognitive impairment/dementia and parkinsonism coexist: corticobasal syndrome/corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, and frontotemporal dementia with parkinsonism linked to chromosome 17. The clinical, neuropsychologic, neuroradiologic, and neu- ropathologic similarities and differences in these disorders are compared and contrasted with each other and with Alzheimer's disease, Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies, highlighting the features critical for identifying the correct diagnosis. -- Rapidly Progressive Dementia -- Michael D. Geschwind, Aissa Haman, and Bruce L. Miller -- Rapidly progressive dementias (RPDs) are neurologic conditions that develop subacutely over weeks to months or, rarely, acutely over days. In contrast to most dementing conditions that take years to progress to death, RPD quickly can be fatal. It is critical to eval-uate patients who have RPD without delay, usually in a hospital setting, as they may have a treatable condition. This review dis-cusses a differential diagnostic approach to RPD, emphasizing neurodegenerative, toxic and metabolic, infectious, autoimmune, neoplastic, and other conditions to consider. -- Normal Pressure Hydrocephalus -- Neill R. Graff-Radford -- Doctors find the management of normal pressure hydrocephalus (NPH) difficult because their diagnosis often is uncertain and the treatment with shunt surgery carries a significant risk. With the aim of bringing to the attention of physicians the useful, but largely anecdotal, information available regarding this problem, this article discusses the epidemiology, reasons why the diagnosis is difficult, differential diagnosis, features of the history, examination, neuropsychologic assessment, radiologic evaluation, and special tests that may help clinicians with management. -- Prion Disease -- Eric Eggenberger -- Prion diseases are a unique group of neurologic diseases caused by an abnormal protein conformation. Prion diseases encompass genetic, sporadic, iatrogenic, and acquired conditions in humans and other mammals. Although they are relatively rare, they produce a diverse array of symptoms, uniformly are fatal, and provide important information about proteins and degenerative neurobiol-ogy in addition to lessons about animal and human food chains. -- Neuroimaging in Dementia -- Jennifer L. Whitwell and Clifford R. Jack Jr -- Neuroimaging has become increasingly important in the clinical assessment and diagnosis of dementia. Structural imaging with MRI and functional imaging techniques, such as positron emission tomography and single photon emission CT, increasingly are used to aid in the differential diagnosis and early detection of dementia. Imaging techniques also can track disease progression over time and may be useful to monitor treatment effects. The most important development in the field over the past decade is the ability to image amyloid in the brain. This technique will revolutionize patient management and care. -- -- ISBN 9781416050926

Unser Preis

EUR 48,00

(inkl. MwSt.)

Versandkostenfrei innerhalb Deutschlands

Aufgenommen mit whBOOK

Sicheres Bestellen - Order-Control geprüft!